Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Big Pharma teams up to defeat drug pricing proposal in California

California wants to cap drug prices, but Big Pharma isn't having it. Amid growing backlash over drug pricing, companies such as Johnson & Johnson and Bristol-Myers Squibb are funneling millions of dollars into stamping out a new proposal that would curb drug spending in the state.

Bristol takes aim at three more hep C niches with Daklinza

In the face of hefty hep C competition from Gilead and AbbVie, can Daklinza profit from a set of niche uses?

U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer

Merck's Keytruda got a green light from the U.K.'s cost-effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.

Can Daklinza profit from a set of niche hep C uses? BMS may soon find out

Gilead and AbbVie may be dominating the hep C field with their next-gen combo treatments, but that doesn't mean there's no room for other companies to sneak in.

Bristol-Myers shells out $14.7M in China bribery settlement

Bristol-Myers Squibb is the latest Big Pharma to pay up for bribery in China. The U.S.-based drugmaker agreed to a $14.7 million settlement with the Securities and Exchange Commission, to wrap up charges that its Chinese joint venture shelled out cash and other incentives to boost scripts for its drugs.

Bristol-Myers wins $256K nod for Opdivo-plus-Yervoy in melanoma

Bristol-Myers Squibb continued its immuno-therapy march today with a combo approval in melanoma. The pairing of its older med Yervoy and new PD-1 cancer-fighter Opdivo won the FDA's green light for patients with advanced melanoma and a particular genetic variation.

Bristol picks ZS to handle commercial analytics in vendor consolidation move

The deal makes ZS Bristol's primary vendor in the sector, allowing the Big Pharma to trim the list of vendors with which it works to analyze commercial data.

Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you

Checkpoint inhibitors Opdivo from Bristol-Myers Squibb and Keytruda from Merck are racing to rack up oncology indications in a range of cancer areas. But with Opdivo vaulting toward a kidney cancer approval, the collective group is about to claim its "first casualty" of the "paradigm shift" toward immuno-oncology drugs, in the words of Bernstein analyst Tim Anderson.

BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tag

Last July, Bristol-Myers Squibb put an early end to a late-stage study that showed its immunotherapy drug, Opdivo, looked good in patients with advanced kidney cancer. And now, it's one step closer to landing a nod in that population.

Bristol-Myers' latest PD-1 win could pave the path to earlier use

Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.